Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I trial of PSW-1025 targeted alpha therapy in castration-resistant prostate cancer
jRCT2051240038Phase 1Active, not recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- May 2024
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of [211At]PSMA-5 in castration-resistant prostate cancer (CRPC), sponsored by Japan Agency for Medical Research and Development. Primary endpoints: Adverse events and Dose-limiting toxicity after single administration. Started May 2024; status: active, not recruiting.
02
Drugs
[211At]PSMA-5
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on jRCT2051240038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051240038.